New Hope, PA, United States of America

Ruowei Mo

USPTO Granted Patents = 3 


Average Co-Inventor Count = 12.6

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2019-2022

Loading Chart...
Loading Chart...
3 patents (USPTO):

Title: Innovations by Ruowei Mo in Arrhythmia Treatment

Introduction

Ruowei Mo is a notable inventor located in New Hope, PA, renowned for his contributions to the field of pharmaceuticals. With a total of three patents to his name, Mo has made significant strides in developing therapeutic solutions for the treatment of arrhythmia.

Latest Patents

Ruowei Mo’s latest patent focuses on Naphthyridinone derivatives and their application in treating arrhythmia. This invention encompasses a compound of formula (I) or a pharmaceutically acceptable salt thereof, with specific definitions for R, R-R, X, and X as outlined in the patent document. The invention not only describes methods for manufacturing these compounds, but also their therapeutic uses. Additionally, it offers a combination of pharmacologically active agents and a pharmaceutical composition aimed at enhancing treatment options for patients suffering from arrhythmia.

Career Highlights

Mo is affiliated with Novartis AG, a leading global healthcare company. His work within this organization has been instrumental in advancing pharmaceutical innovations that address critical health issues. His patent achievements reflect his dedication to research and development in the pharmacological field.

Collaborations

In his career, Ruowei Mo has collaborated with esteemed colleagues, including Guillaume Barbe and Gregory Raymond Bebernitz. These partnerships highlight the importance of teamwork in driving innovation and enhancing therapeutic methodologies.

Conclusion

Ruowei Mo’s contributions to the medical field through his inventions underscore the critical role of innovation in developing effective treatments for arrhythmia. As he continues to build on his research, his work may pave the way for further advancements in pharmacology and patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…